Search Results

There are 31087 results for: content related to: Sclerosing mesenteritis: An ergot-related complication of pergolide therapy in Parkinson's disease?

  1. Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide

    Movement Disorders

    Volume 21, Issue 4, April 2006, Pages: 586–587, Eun Joo Chung, Won Tae Yoon, Ji-Youn Kim and Won Yong Lee

    Version of Record online : 15 FEB 2006, DOI: 10.1002/mds.20813

  2. Pergolide for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    C E Clarke and Julie Speller

    Published Online : 26 APR 1999, DOI: 10.1002/14651858.CD000235

  3. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

    Movement Disorders

    Volume 16, Issue 5, September 2001, Pages: 858–866, William Koller, Andrew Lees, Miroslava Doder, Mariese Hely and the Tolcapone/Pergolide Study Group

    Version of Record online : 20 SEP 2001, DOI: 10.1002/mds.1175

  4. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study

    Movement Disorders

    Volume 21, Issue 3, March 2006, Pages: 343–353, Wolfgang H. Oertel, Erik Wolters, Cristina Sampaio, Santiago Gimenez-Roldan, Bruno Bergamasco, Max Dujardin, Donald G. Grosset, Guy Arnold, Klaus L. Leenders, Hans-Peter Hundemer, Alberto Lledó, Andrew Wood, Paul Frewer and Johannes Schwarz

    Version of Record online : 6 OCT 2005, DOI: 10.1002/mds.20724

  5. Valvular heart disease in patients exposed to pergolide: insights from the clinical presentation

    Pharmacoepidemiology and Drug Safety

    Volume 21, Issue 3, March 2012, Pages: 276–280, Ashok Krishnaswami, Kathleen B. Albers, Robin D. Fross, James J. Jang, Sarah B. Berkheimer, Valerie C. Kwai Ben and Stephen K. VanDenEeden

    Version of Record online : 9 JAN 2012, DOI: 10.1002/pds.2274

  6. You have free access to this content
    Dopamine depletion and subsequent treatment with l-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum

    Journal of Neurochemistry

    Volume 102, Issue 3, August 2007, Pages: 699–711, Evgeny Bychkov, M. Rafiuddin Ahmed, Kevin N. Dalby and Eugenia V. Gurevich

    Version of Record online : 21 MAR 2007, DOI: 10.1111/j.1471-4159.2007.04586.x

  7. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction

    Journal of Veterinary Pharmacology and Therapeutics

    Volume 40, Issue 2, April 2017, Pages: 158–164, D. McFarlane, H. Banse, H. K. Knych and L. K. Maxwell

    Version of Record online : 15 JUN 2016, DOI: 10.1111/jvp.12339

  8. You have free access to this content
    Cost-Effectiveness of Pergolide Compared to Bromocriptine in the Treatment of Parkinson's Disease: A Decision-Analytic Model

    Value in Health

    Volume 4, Issue 4, July 2001, Pages: 308–315, Peter Davey, Narayan Rajan, Michael Lees and Michael Aristides

    Version of Record online : 28 JUN 2008, DOI: 10.1046/j.1524-4733.2001.44039.x

  9. Diagnosis and management of pergolide-induced fibrosis

    Movement Disorders

    Volume 20, Issue 4, April 2005, Pages: 512–513, Naushad Hirani, Charles C. Bayliff and David G. McCormack

    Version of Record online : 28 FEB 2005, DOI: 10.1002/mds.20443

  10. Pergolide versus bromocriptine for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Carl E Clarke and Julie Speller

    Published Online : 26 APR 1999, DOI: 10.1002/14651858.CD000236

  11. Science-in-brief: Report from the Second European Equine Endocrinology Symposium

    Equine Veterinary Journal

    Volume 46, Issue 5, September 2014, Pages: 525–528, A. E. Durham, R. J. Geor, J. L. Ireland, C. M. McGowan and H. C. Schott

    Version of Record online : 7 AUG 2014, DOI: 10.1111/evj.12313

    Corrected by:

    ERRATUM: Erratum

    Vol. 46, Issue 6, 778, Version of Record online: 15 OCT 2014

  12. Dopamine agonists for the treatment of restless legs syndrome

    Intervention Review

    The Cochrane Library

    Hanna Scholz, Claudia Trenkwalder, Ralf Kohnen, Levente Kriston, Dieter Riemann and Magdolna Hornyak

    Published Online : 15 MAR 2011, DOI: 10.1002/14651858.CD006009.pub2

  13. You have free access to this content
    Treatment of restless legs syndrome: An evidence-based review and implications for clinical practice

    Movement Disorders

    Volume 23, Issue 16, 15 December 2008, Pages: 2267–2302, Claudia Trenkwalder, Wayne A. Hening, Pasquale Montagna, Wolfgang H. Oertel, Richard P. Allen, Arthur S. Walters, Joao Costa, Karin Stiasny-Kolster and Cristina Sampaio

    Version of Record online : 16 OCT 2008, DOI: 10.1002/mds.22254

  14. Trial of subtherapeutic pergolide in de novo Parkinson's disease

    Movement Disorders

    Volume 20, Issue 3, March 2005, Pages: 363–366, Katherine Grosset, Donald Grosset and Andrew Lees

    Version of Record online : 3 DEC 2004, DOI: 10.1002/mds.20361

  15. You have free access to this content
    Pharmacokinetics of Pergolide Mesylate in Horses

    Equine Veterinary Journal

    Volume 45, Issue S44, September 2013, Page: 19, D.I. Rendle, K.J. Hughes, G. Doran and S. Edwards

    Version of Record online : 9 SEP 2013, DOI: 10.1111/evj.12145_47

  16. A Comparison of Pergolide and Bromocriptine in the Initial Rehabilitation of Cocaine Dependence

    The American Journal on Addictions

    Volume 3, Issue 2, Spring 1994, Pages: 144–150, Robert Malcolm, Joem D. Phillips, Kathleen T. Brady and John R. Roberts

    Version of Record online : 18 FEB 2010, DOI: 10.1111/j.1521-0391.1994.tb00381.x

  17. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease

    Movement Disorders

    Volume 26, Issue S3, October 2011, Pages: S2–S41, Susan H. Fox, Regina Katzenschlager, Shen-Yang Lim, Bernard Ravina, Klaus Seppi, Miguel Coelho, Werner Poewe, Olivier Rascol, Christopher G. Goetz and Cristina Sampaio

    Version of Record online : 21 OCT 2011, DOI: 10.1002/mds.23829

  18. Diagnosis and management of pergolide-induced fibrosis

    Movement Disorders

    Volume 19, Issue 6, June 2004, Pages: 699–704, Pinky Agarwal, Stanley Fahn and Steven J. Frucht

    Version of Record online : 19 MAY 2004, DOI: 10.1002/mds.20200

  19. A “combined” levodopa test as a useful method for evaluating the efficacy of dopamine agonists: Application to pergolide and bromocriptine

    Movement Disorders

    Volume 10, Issue 5, September 1995, Pages: 668–671, Dr. A. M. Bonnet, I. Serre, R. Marconi, Y. Agid and B. Dubois

    Version of Record online : 12 OCT 2004, DOI: 10.1002/mds.870100522

  20. Pergolide compared with bromocriptine in Parkinson's disease: A multicenter, crossover, controlled study

    Movement Disorders

    Volume 9, Issue 4, 1994, Pages: 431–436, Dr. G. Pezzoli, E. Martignoni, C. Pacchetti, V. A. Angeleri, P. Lamberti, A. Muratorio, U. Bonuccelli, M. De Mari, N. Foschi, E. Cossutta, F. Nicoletti, F. Giammona, M. Canesi, G. Scarlato, T. Caraceni and E. Moscarelli

    Version of Record online : 12 OCT 2004, DOI: 10.1002/mds.870090409